Considerations for Oncology Nurses—Individualizing the Management of Acute Myeloid Leukemia: Genomics, Targeted Therapeutic Options, and Treatment Sequencing
FACULTY
Michael R. Grunwald, MD
Chief, Leukemia Division
Department of Hematologic Oncology and Blood Disorders
Levine Cancer Institute
Charlotte, NC
PROGRAM OVERVIEW
This online activity will cover the treatment and management of patients with Acute Myeloid Leukemia (AML).
TARGET AUDIENCE
This activity is designed to meet the educational needs of US-based oncology nurses, hematologists/oncologists, and other HCPs that form the multidisciplinary team involved in the management of patients with AML.
LEARNING OBJECTIVES
On completing the program, attendees should be able to:
- Review therapeutic targets in AML, including BCL-2, FLT3, IDH1, IDH2, CD33, and the apoptotic and hedgehog signaling pathways
- Assess AML patients by risk categories based on cytogenetic and molecular information
- Describe current and novel therapeutic approaches for patients with previously untreated and relapsed/refractory AML
- Plan individualized treatment strategies of sequential and combination regimens for patients with AML by integrating new agents into the current treatment paradigm
- Discuss strategies that will improve communication, engagement, education, and decision making with AML patients and their healthcare providers
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this online activity for a maximum of 1.0 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the online activity.
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in the long-term treatment and management of patients with Acute Myeloid Leukemia.
CNE Credits: 1.0 ANCC Contact Hour.
CNE ACCREDITATION STATEMENT
Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing. Awarded 1.0 contact hour(s) of continuing nursing education of RNs and APNs.
ONCC STATEMENT
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturers of any commercial products and/or providers of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTERESTS
Faculty
Michael R. Grunwald, MD, has received consulting fees for AbbVie, Inc., Incyte, Amgen, Cardinal Health, Celgene, Pfizer, Agios, Merck, Daichi-Sankyo, and Trovagene. He has stocks with Medtronic. Dr. Grunwald has also received research funding from Incyte, Forma Therapeutics, Janssen, Genentech/Roche, and Novartis.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer-reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
The staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, General Manager of Med Learning Group has nothing to disclose.
Christina Gallo, SVP, Educational Development of Med Learning Group has nothing to disclose.
Ana Maria Albino, Program Manager of Med Learning Group has nothing to disclose.
Nicole Longo, DO, FACOI, Director of Medical and Scientific Services of Med Learning Group has nothing to disclose.
Lauren Welch, MA, VP of Accreditation and Outcomes of Med Learning Group has nothing to disclose.
Brianna Hanson, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME/CNE credit for this enduring activity. To receive CME/CNE credit participants must:
1. Read the CME/CNE information and faculty disclosures.
2. Participate in the enduring activity.
3. Complete pre-and-post survey.
4. Submit the evaluation form online.
You will receive your certificate as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are science-based.
This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at info@medlearninggroup.com
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/
RELEASE DATE: December 16, 2019
EXPIRATION DATE: December 16, 2020
